Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Growth

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best 1M Momentum Mid Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2026Mar2025Mar2024Mar2023Mar2022
   Core EBITDA Growth(%) 31.25-1.3818.82-27.0420.67

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is 31.25 based on Mar2026 Consolidated results.
Year Core EBITDA Growth
Mar202631.25
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2026 31.25
Positive
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹51,108.8 Cr 8.9% 3.6% 58.5% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹426,662.0 Cr 2% -4.4% 3.7% Stock Analytics
DIVIS LABORATORIES ₹257,903.0 Cr 7.1% 2.5% 46.6% Stock Analytics
TORRENT PHARMACEUTICALS ₹176,306.0 Cr 1.4% -5.7% 27.6% Stock Analytics
DR REDDYS LABORATORIES ₹112,699.0 Cr 3.6% 8% 4.2% Stock Analytics
CIPLA ₹111,489.0 Cr 2% -0.2% -14.3% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

8.9%

3.6%

58.5%

SENSEX

1.8%

2.3%

-11.9%


You may also like the below Video Courses